Scales measuring perceptions of pain can include numeric rating scales (NRS), visual analogue scales (VAS) and descriptor scales using words (adjectival). With the increased use of electronic data capture in clinical trial settings, such scales have been migrated to numerous platforms. After conducting a brief literature review, there was found to be a lack of research on the impact that migration of such pain scales can have on the efficacy of the scales. The objective of this study was to deploy three pain scales in different formats and on different platforms, and to explore preferences and perceived differences in patients who experience daily pain. METHODS: Twelve participants diagnosed with a range of conditions resulting in pain were interviewed in a qualitative interview setting. All participants completed three pain scales in different formats: NRS (11-, 9-, and 7-points; portrait/ landscape), VAS (horizontally/ vertically; portrait/ landscape) and adjectival scale (increasing/ decreasing severity). All scales were presented in three modes of administration: paper, handheld device and tablet device. Participants were asked about perceived differences and their preferences of the different scales, formats, and modes of administration. RESULTS: The NRS and adjectival scale were preferred equally (nϭ5). Participants expressed an almost unanimous preference for the 11-point NRS and increasing severity adjectival scale, across all administration modes. In contrast, the VAS was the least preferred scale (nϭ7) due to difficulty with interpretation. Participants expressed no usability problems with the tablet or handheld devices, but the tablet was preferred overall because of the bigger screen. CONCLUSIONS: Although the sample size makes generalising these findings difficult, this exploratory study suggests that the preferred pain scales may provide higher quality data as they are easier to interpret, and therefore minimise error and patient burden. Further evidence, particularly quantitative, is required to support these preliminary findings. 
PRM118 METHODOLOGY FOR NEUROPSYCHOLOGICAL ASSESSMENT WORDLIST ADAPTATION

OBJECTIVES:
Effective translation and adaptation of neuropsychological assessments is paramount to the successful collection of data in a global context. The structure and content of neuropsychological assessments requires specific processes for translation and adaptation to ensure appropriate understanding in each target language. Word list adaptation requires particular consideration, as various criteria must be met within and between wordlists -including but not limited to frequency, familiarity and cultural relevance to the target population, number of syllables, and avoidance of homonyms and repeated words. This review highlights important considerations for creation of target language word lists, and solutions for determining appropriate adaptation methodologies. METHODS: A review of previous translations of neuropsychological assessments, such as the ADAS, FC-SRT, RBANS, MoCA, and MMSE, was performed. A review of translation procedures, developer involvement, guidelines for adaptation, translation methodology, linguistic decisions, and word list creation was conducted. RESULTS: Key solutions to ensure successful adaptation of wordlists include: 1) Outline all criteria used to develop the English word lists and assessment, 2) Create clear guidelines for adaptation of word lists in collaboration with the developer, if guidelines are not already available, 3) Employ a specialized project team of project managers, native-speaking medical linguists, and native-speaking neuropsychologists possessing extensive expertise in the relevant neuropsychological assessments. 4) Depending upon the assessment and the context of use, additional testing of the word lists with local populations to ensure comprehension may be warranted. CONCLUSIONS: Neuropsychological assessments and word lists require specialized translation and adaptation methodologies to ensure appropriate comprehension by the target population. Developer involvement in the creation of adaptation guidelines, and neuropsychologist involvement in the adaptation process are critical to ensuring adaptation is conducted appropriately. Further research is required to outline clear guidelines for situations requiring additional testing of the word lists with local populations to ensure comprehension. 
PRM119 MAPPING BETWEEN COMPOSITE MEASURES IN PSORIATIC ARTHRITIS AND THE SF-6D: ANALYSIS FROM THE GRACE DATASET
OBJECTIVES:
Mapping or cross-walking is an accepted methodology for calculating utilities. Different models have been proposed for mapping from disease-specific quality-of-life (QOL) measures to generic QOL measures. Much of this work has been done using data from rheumatoid arthritis cohorts and using measures specific to RA. The objectives of this study are to test various statistical models to determine which provides the best fit for a psoriatic arthritis (PsA) cohort using both newly developed composite disease measures and established measures. The study also aimed to determine whether the composite disease measures provide a better estimate of utility over other measures and which components of the composite measures influence the relationship with QOL. METHODS: The data was made available from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) which collected data from an international cohort of PsA patients. Different regression models were used to estimate the relationship between the generic QOL measure, SF-6D and disease specific measures (HAQ,Composite Disease Activity Index (CPDAI), Psoriatic ArthritiS Disease Activity Score (PASDAS) and the Arithmetic Mean Desirability Function Score (AMDF). Model fit was determined using the R 2 statistic, root mean square error, Akaike information criterion; regression coefficients are also presented. RESULTS: The optimal model for each of the disease specific measures and SF-6D was a multiple regression model. The difference in model fit between the linear and multiple regression models was greatest for the composite disease measures specific to PsA. The CPDAI and AMDF provided the best fit to utility score followed by the PASDAS. CONCLUSIONS: PsA is a heterogeneous disease for which composite disease measures may be more appropriate than measures such as the HAQ. This study provides mapping coefficients, allowing utility estimation from these measures which may be collected in trials where no preference-based utility measure has been used. Burke, 2011; Gwaltney, 2012) , the FDA have not published guidelines on ClinRO measures to support label claims. This is surprising given that the ratio of label claims based on ClinRO's is approximately three ClinRO's to every PRO measure (Burke, 2010) . METHODS: We conducted a review of the literature to ascertain the general level of use of ClinRO's and to find examples of widely used ClinRO's. The available evidence for these ClinRO's was then assessed by the standards of the PRO guidance, specifically in relation to content and construct validity, reliability and other psychometric properties.
PRM120 PATHWAYS TO EFFECTIVE CLINRO DOSSIER DEVELOPMENT
RESULTS:
The literature review revealed that ClinRO's are common endpoints in clinical trials. However, it was also apparent from the sample of ClinRO's reviewed, that they fail to meet the evaluative standards prescribed by the FDA particularly in being "well defined and reliable". CONCLUSIONS: ClinRO's used as endpoints in clinical trials to support FDA label claims may lack the required evidence set out in the FDA PRO guidance document. Specifically, many ClinRO's have been developed by clinicians, and widely accepted by clinical peers, without undergoing psychometric evaluation. If the FDA were to evaluate ClinRO's to the same standards as PRO's, the ratio of label claims between ClinRO's and PROs may decrease significantly. OBJECTIVES: Osteoarthritis (OA) also known as degenerative arthritis or degenerative joint disease, is a group of mechanical abnormalities involving degradation of joints. The daily-life of OA patient is considerably disturbed. The burden's concept assesses the individual burden, measuring the patient's disability generated by the disease in a broad sense.The aim of our study was to explore, using a questionnaire, how the burden of the OA affected a daily life, with the objective to better anticipate difficulties and thus provide better care METHODS: The development of the questionnaire we propose here was inspired by the construction of general QoL-questionnaires. Two steps are required for the development:, the creation in three stages following a strict methodological process involving a multidisciplinary team (doctors, social workers) and patients with OA who were interviewed; Secondly, the validation of the questionnaire by testing its reliability, its construct validity and its reproducibility. A cognitive debriefing was conducted to ensure its reproducibility. RESULTS: A population of 198 patients with OA was enrolled to answer to the questionnaire,( with SF12 and PGWI). We obtain a questionnaire called "Burden-Osteoartritis-New-Scale-BONeS". Exploratory assessments realized with a population showed that the concept of burden could be structured around 5 components: autonomy, daily life, family and personal relationships, work and psychological impact. 41 preliminary items were identified at the end of the verbatim. A final analysis managed to reduce to 28 items and a cognitive debriefing allowed to ensure its reproducibility. CONCLUSIONS: Chronic pathologies such as OA which remains a rare and incapacitating illness are difficult to assess by clinical or QoL aspects alone as their impact can be multidimensional. "BONeS" takes them all into consideration in order to explain every angle of the handicap generated. Our next objective is to develop the "BONeS" in German, Italian and Spanish with a cross cultural validation. 
PRM121 BURDEN OF OSTEOARTHRITIS :DEVELOPMENT OF A QUESTIONNAIRE
PRM122 ATOPIC DERMATITIS ON FAMILIES: CREATION OF A SPECIFIC BURDEN QUESTIONNAIRE
OBJECTIVES:
Atopic dermatitis is one of the most common chronic inflammatory skin diseases. It has an estimated prevalence of between 5 and 30% in children, and is steadily increasing in industrialized countries. Pruritus, xerosis and inflammation are the main symptoms. METHODS: The ABS questionnaire (Atopy Burden Score) consists of 19 items, structured around 5 components (Everyday Life, Leisure, Family Life, Budget, Work and Privacy). It was distributed to a random sample of families consulting at the Necker Hospital. The ABS was accompanied by SF12 and PGWBI to obtain internal and external validation, and by the PO-SCORAD to assess the level of severity. RESULTS: 58 were considered evaluable. Internal validity was measured by Cronbach's alpha, which is equal to 0.81, reflecting a good homogeneity of the 19 questionnaire items. The mean PGWBI score is 51.82Ϯ14.28. The scores are significantly different depending on the severity of the atopy. Families' quality of life, measured using the SF12, revealed no deterioration in the physical component (52.83Ϯ7.08). The ABS score is correlated with the scores of the questionnaires used, thus confirming external validity.The mean score calculated from the ABS is 48.17Ϯ18.36. The score increases with the severity of the atopy.A statistically significant difference is observed between the three severity groups, i.e. mild, moderate and severe, with scores of 30.63Ϯ10.89, 42.55Ϯ15.72 and 62.62Ϯ13.59 respectively. Each of the five components is also correlated with the severity of atopy, which opens the door for more detailed analyses of sensitivity to change. CONCLUSIONS: The internal and external validity of our questionnaire were confirmed. ABS is correlated with the severity of atopy. This is currently being done as part of a program aimed at evaluating the therapeutic education and treatment of children in hydrotherapy centers. Following cultural and linguistic validation, the ABS is now available in US English, Spanish, German and Italian. 
PRM124 TRANSLATION OF THE ALCOHOL TIMELINE FOLLOWBACK (TLFB) IN 4 LANGUAGES
OBJECTIVES:
The Alcohol Timeline Followback (TLFB), developed in English (US), is a drinking assessment method that obtains estimates of daily drinking. Using a calendar, people provide retrospective estimates of their daily drinking over a specified time period that can vary up to 12 months from the interview date. Several memory aids can be used to enhance recall, such as 24 key dates and country specific holidays for calendar year 2012 serving as anchors for reporting drinking, or use of standard drink conversion. The objective of this study is to present the translation of the TLFB in Czech, Slovak, Italian, and Hungarian. METHODS: The following translation method was used: concept definition, forward translation in the target languages, backward translation and test on five individuals (cognitive interviews) in each country. RESULTS: Difficulties encountered during the process were twofold: 1) ensuring that the standard drink conversions were correct, i.e., reflecting US standards, and culturally appropriate, and 2) adapting the 24 US key anchor dates to each country. For the standard drink conversion, the main change was the use of the metric system instead of the US customary units, i.e., use of liter and sub-units instead of ounces. In addition, quantities had to be adapted to fit cultural uses. For instance, in Slovakia and Czech Republic, "one 12 oz can/bottle of beer" was adapted to "one beer in a can / bottle of 0.5 liter." Thirteen anchor dates in the US calendar had to be deleted in all countries, e.g., Martin Luther King day (01/16/2012) or President's Day (02/20/2012), as culturally inappropriate. Other key dates were added, e.g., Labor Day (05/01/2012) or Easter Monday (04/09/2012) in all four countries. Patients were key in discussing changes or proposing solutions. CONCLUSIONS: The multistep process proved crucial to ensure cultural relevance and cross-cultural equivalencies across different languages.
PRM125 WHOSE VALUES IN HEALTH? A COMPARISON OF ADULT AND ADOLESCENT VALUES FOR THE CHU9D AND AQOL-6D
Ratcliffe J Flinders University, Daw Park, South Australia, Australia
OBJECTIVES:
The Child Health Utility-9D (CHU9D) and Assessment of Quality of Life-6D (AQOL-6D) currently represent the only two generic preferences based instruments developed for application in the economic evaluation of new health technologies with both adult and adolescent specific scoring algorithms attached to them. The main objective of this study was to compare and contrast the application of adult and adolescent scoring algorithms for the CHU9D and AQOL-6D in valuing the health of a community based sample of adolescents. METHODS: A web based survey including the CHU9D and the AQOL-6D was developed for administration to adolescents residing in Australia, aged 11-17 years (nϭ500). Individual responses to both instruments were converted to health state utility values by applying [1] adult and [2] adolescent scoring algorithms pertaining to each instrument. RESULTS: Both the AQOL-6D and CHU9D discriminated well according to health status and long standing illness regardless of the scoring algorithm employed. However, important discrepancies were found in that employment of the adolescent algorithm resulted in consistently lower mean health state values for the CHU9D but consistently higher mean health state values for the AQOL-6D relative to employment of their respective adult algorithms and these differences were found to be statistically significant for both instruments (pϽ0.05).
CONCLUSIONS:
The findings from this study concur with an expanding evidence base highlighting discrepancies in adult and adolescent values for identical health states. The differences in adolescent and adult values were more profound for the CHU9D, particularly in relation to mental health impairment states, and may be significant enough to strongly affect the findings of cost effectiveness studies and ultimately health care policy. There are important differences between both the CHU9D and AQOL-6D descriptive systems and the methods of valuation utilized for each instrument which may impact on the health state utility values generated by each scoring algorithm. 
PRM126 CHOICE-BASED VALUATION OF THE SF-12V1
OBJECTIVES:
To value SF-12v1 outcomes from the perspective of US adults METHODS: The paired comparisons of the SF-12v1 items were incorporated into a larger, online survey of US health preferences using an invitation-only panel of US respondents. This pivoted discrete choice experiment (DCE) collected 28,080 responses on 408 pairs from 936 respondents. The quantal response model includes an additive multi-attribute regression within a stacked logit distribution to allow for excess kurtosis due to satisficing. RESULTS: On a quality-adjusted life year scale, 30 out of 31 decrements were significantly non-zero at 0.05 significance level. The only insignificant decrement, LE2, represented the decrease in energy from "You have a lot of energy all of the time" (i.e., manic) to "You have a lot of energy most of the time." The value of pits was 0.1532 QALY (95% CI 0.1022,0.1970) and was significantly better than dead (0). CONCLUSIONS: This is the first national valuation study of the SF-12v1 descriptive system. Instead of reducing domains of complex descriptive systems to single items (e.g., SF-36v1), DCE allows for choice-based valuation of all outcomes, regardless of the number of items.
PRM127 MEASURING QUALITY OF LIFE IN MENTAL HEALTH: ISSUES AND CHALLENGES
Lewis L, Taylor M, Roberts S University of York, York, UK OBJECTIVES: To undertake a detailed review of the existing use of utility scores in models evaluating the cost-effectiveness of mental health conditions. The study also aimed to identify the key issues and challenges that are faced by decision makers attempting to evaluate the benefits of treatments for mental health. METHODS: A detailed review was undertaken to identify a wide range of studies that used modelling techniques to estimate the cost-effectiveness of interventions for different mental health conditions. The review included studies of treatments for bi-polar disorder, schizophrenia, depression, anxiety, dementia, eating disorders. The review determined whether each model contained utility data and how those utility data were derived and reported. Quality grades were assigned to each study based on the appropriateness of use of the utility data. RESULTS: Nearly all cost-effectiveness models in mental health contained utility-based outcomes, such as quality-adjusted life years. However, the quality of data used to generate those outcomes varied considerably, and many studies contained poor data or data used in an inappropriate manner. In addition to the expected limitations of instruments used to derive quality of life scores, common misuses of data included: 1) inappropriate timing of elicitation (for instance, applying quality of life scores at diagnosis to the whole duration of the model); 2) failing to account for comorbidities and confounding factors; 3) assumptions around missing data; and 4) failing to account for the patient's history when defining their current health state. CONCLUSIONS: The use of utility data in mental health models varies widely, and most models cannot be considered to provide reliable and robust data. For models to be useful to decision makers, it is recommended that a consistent approach toward measuring quality of life in patients with mental health conditions should be used where possible. 
PRM128 DEVELOPMENT OF A TRANSLATION EVIDENCE TRACKING TOOL TO COMPLY WITH THE FDA REVIEW REQUIREMENTS FOR THE TRANSLATION OF PRO INSTRUMENTS
OBJECTIVES:
In its guidance on the use of PRO measures, the FDA specifies the areas to be addressed in PRO documents provided for review. Regarding language translation, four areas are listed: (A) Process used to translate and culturally adapt the instrument for populations that will use them in the trial; (B) Description of patient testing, language-or culture-specific concerns, and rationale for decisions made to create new versions; (C) Copies of translated or adapted versions; and (D) Evidence that content validity and other measurement properties are comparable between the original and new instruments. The objective of this study is to present the development of an evidence tracking tool to organize the evidence generated during the translation of a PRO instrument to comply with the FDA review requirements. METHODS: 1) Review of the process used to translate PRO instruments, and of the evidence provided during the translation process; 2) Organization of the evidence according to the four areas listed in the FDA guidance (excluding measurement properties); and 3) Development of a standardized tool to present this information. RESULTS: The translation evidence tracking tool is a table divided into three parts. Part 1 (translation background information) gathers the information requested in areas A and C. Part 2 (translation report) provides the evidence required in area B. Part 3 (content validity) concerns the comparability of content validity. For this part, it was assumed that comparability will depend on: (1) A clear definition and understanding of the concepts to be translated; and (2) The involvement of trained professionals. Hyperlinks are provided in each part of the table to lead to the evidence documents required for each area listed by the FDA.
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